Compare Twist Bioscience Corp (TWST) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Wix.Com Ltd — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Wix.Com Ltd trades at $73.87 (market cap $3.04B). The key difference: Twist Bioscience Corp is far larger — about 2.8× Wix.Com Ltd's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| TWST | WIX | |
|---|---|---|
Market Cap | $8.42B | $3.04B |
Sector | Health | Technology |
52-Week High | $153.10 | $184.24 |
52-Week Low | $24.16 | $40.43 |
Enterprise Value | $8.35B | $4.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
WIX trades at $72.72, down 4.58% in the last session, with a bearish technical signal and negative net cash flow of -$344.06M in 2025. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19% for 2026. The stock faces multiple class action lawsuits alleging securities fraud, with a deadline of September 22, 2026, adding legal overhangs.
The outlook is mixed: analyst consensus is a Buy with a $73.36 target, near the current price, but risks from litigation and volatile earnings pose headwinds. Investment opportunity hinges on execution amid competitive pressures, while downside protection is limited by weak profitability and negative shareholder equity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
